1. 1720PIs it appropriate to use a fixed prophylactic dose of enoxaparin for hospitalized cancer patients? Results from a prospective tertiary referral single center study. (23rd October 2018) Authors: Maurice-Dror, C; Litvak, M; Keren, A; Akerman, S; Brenner, B; Haim, N; Nadir, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A‐4 3‐O‐phosphate. (November 2014) Authors: Williams, L J; Mukherjee, D; Fisher, M; Reyes‐Aldasoro, C C; Akerman, S; Kanthou, C; Tozer, G M Journal: British journal of pharmacology Issue: Volume 171:Number 21(2014:Nov.) Page Start: 4902 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗